Orion Oyj

ORNBV

Equity

ISIN FI0009014377 / Valor 2553367

NASDAQ Helsinki Ltd, Equities (2025-11-21)

EUR 59.95+0.25%

Orion Oyj
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Orion Oyj is a globally operating Finnish pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests. The company places a strong emphasis on collaboration and networking across its entire value chain, partnering with other entities in the pharmaceutical industry to enhance its research and development, manufacturing capabilities, and marketing reach. Through these partnerships, Orion aims to expand its product portfolio and strengthen its presence in the international market. While the company's specific product offerings are not detailed in the provided source, Orion's business model is indicative of a comprehensive approach to pharmaceutical and healthcare solutions, leveraging external expertise and resources to bolster its operations and product offerings.

Summarized from source with an LLMView SourceSector: Healthcare

Net sales and milestones

Reported Q3 2025 net sales: EUR 423.2m (Q3 2024: EUR 471.3m). The comparison period included EUR 130m of milestone receipts; excluding milestones, underlying Q3 net sales were up 24% (vs EUR 341.3m underlying in Q3 2024). In January–September 2025 net sales were EUR 1,194.2m (+7.8% vs prior year).

Profitability

Operating profit Q3 2025: EUR 121.0m (Q3 2024: EUR 202.0m). Excluding prior‑period milestones, underlying operating profit increased 68.1% to EUR 121.0m. January–September operating profit was EUR 303.5m (down 6.3% vs 1–9/2024).

Earnings per share and cash flow

Basic EPS Q3 2025: EUR 0.68 (Q3 2024: EUR 1.14). Cash flow from operations per share Q3 2025: EUR 0.55 (Q3 2024: EUR 0.48). For Jan–Sep 2025 cash flow from operations per share was EUR 1.67 (1.46).

Outlook for 2025

Orion specified its 2025 outlook: net sales now expected EUR 1,640–1,720m (previously EUR 1,630–1,730m) and operating profit EUR 410–490m (previously EUR 400–500m).

R&D and pipeline moves

R&D spend in Q3 2025: EUR 49.8m (+35.8% vs Q3 2024); Jan–Sep R&D EUR 139.8m (+19.4%). Company discontinued ODM‑105 after a negative Phase 2 insomnia trial, will advance ODM‑212 into an extensive Phase 2 programme next year and aims to bring at least one biological candidate into clinical development in 2026.

Product and business division trends

Nubeqa® showed strong growth and received EC approval (July 2025) for use with ADT in metastatic hormone‑sensitive prostate cancer, supporting future sales. Generics & Consumer Health continued solid growth. Branded Products and Animal Health growth was more moderate in Q3, partly due to normal timing of deliveries.

Costs, capex and personnel

Operating expenses rose (sales & marketing and R&D increases cited). Capex Q3 2025: EUR 30.1m (+37.8% vs Q3 2024); Jan–Sep capex EUR 84.6m (+50.3%). Average headcount increased to 3,989 (up 6.2% vs prior year period).

Balance sheet and returns

Interest‑bearing net liabilities were EUR 87.1m (up vs prior period). Equity ratio ~58.5%, gearing ~8.5%. Return on capital employed (before taxes) was 31.0% and return on equity (after taxes) 31.6% for the reported period.

Milestones and royalties detail

Q3 2025 milestone income was minimal (EUR 0.5m) versus EUR 130.5m in Q3 2024; royalties increased to EUR 119.3m (Q3 2024: EUR 69.5m), which helped underlying revenue growth once milestones are excluded.

Summarized from source with an LLMView Source

Key figures

35.1%1Y

23.4%3Y

50.3%5Y

Performance

30.8%1Y

27.1%3Y

27.4%5Y

Volatility